TREMFYA® offers simple and
convenient administration3,4
with impactful QoL outcomes,1
so patients can enjoy the
everyday life they love.
comes with peace of mind.

TREMFYA® One-Press: one click to an easier life3,4




 
98.4% of patients were satisfied with their self-injections.4
  

TREMFYA® offers minimal injections per year3




A single, 100 mg dose every 8 weeks after only 2 starter doses. The recommended dose of Tremfya® is 100 mg by subcutaneous injection at Weeks 0 and 4, followed by a maintenance dose every 8 weeks
 
TREMFYA® offers the convenience of a single injection per dose.3


QoL-Quality of Life.
 
 
 
 
 
 
 
REFERENCES SEE MORE OF THE LATEST DATA
ON THE JANSSEN MEDICAL CLOUD™		 PRESCRIBING
INFORMATION

 
TREMFYA® is indicated for adults with moderate-to-severe plaque
psoriasis (Pso) who are candidates for systemic therapy.10

Tremfya®, alone or in combination with methotrexate (MTX), is indicated
for the treatment of active psoriatic arthritis in adult patients who have
had an inadequate response or who have been intolerant to a prior
disease-modifying antirheumatic drug (DMARD) therapy. 10

Please ensure you review your local Prescribing Information and/or
Summary of Product Characteristics and directly consult
your local Janssen affiliate to address questions.		 Privacy notice  Legal notice

This is published by Janssen Pharmaceutica NV which is solely responsible
for its content. It is intended for EMEA Healthcare professionals.
Third party trademarks used herein are trademarks of their respective owners.
Date of preparation: March 2021.  CP-214600